List of Excipients in Branded Drug DIHYDROERGOTAMINE MESYLATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oceanside Pharmaceuticals	DIHYDROERGOTAMINE MESYLATE	dihydroergotamine mesylate	68682-357	ANHYDROUS DEXTROSE
Oceanside Pharmaceuticals	DIHYDROERGOTAMINE MESYLATE	dihydroergotamine mesylate	68682-357	CAFFEINE
Oceanside Pharmaceuticals	DIHYDROERGOTAMINE MESYLATE	dihydroergotamine mesylate	68682-357	CARBON DIOXIDE

Generic Drugs Containing DIHYDROERGOTAMINE MESYLATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	dihydroergotamine mesylate	0143-9151	ALCOHOL
Hikma Pharmaceuticals USA Inc	dihydroergotamine mesylate	0143-9151	GLYCERIN
Hikma Pharmaceuticals USA Inc	dihydroergotamine mesylate	0143-9151	METHANESULFONIC ACID

What are the Most Frequently-Used Excipients in DIHYDROERGOTAMINE MESYLATE?

# Of NDCs	Excipient
10	ALCOHOL
4	ANHYDROUS DEXTROSE
4	CAFFEINE

Excipient Strategy and Commercial Opportunities for Dihydroergotamine Mesylate

Last updated: February 27, 2026

What is the excipient landscape for Dihydroergotamine Mesylate (DHE)?

Dihydroergotamine mesylate (DHE) is a potent ergot alkaloid used primarily for acute migraine treatment. It is administered via nasal spray, injection, or inhalation. Excipient selection influences drug stability, bioavailability, and patient compliance.

How does excipient selection impact DHE manufacturing?

DHE's formulation challenges include:

• Stability issues: DHE is sensitive to oxidation and moisture.
• Bioavailability: It requires excipients that enhance absorption.
• Patient acceptability: Preference shifts toward non-invasive routes.

Common excipients include:

• Buffers: Citric acid or phosphate buffers maintain pH stability.
• Preservatives: Benzalkonium chloride for nasal or injectable formulations.
• Solubilizers: Propylene glycol enhances solubility.
• Absorption enhancers: Surfactants like polysorbates improve mucosal uptake.

Example formulations

Component	Purpose	Typical Concentration
Citric acid	pH buffering	0.1-0.3%
Benzalkonium chloride	Preservative	0.01-0.02%
Propylene glycol	Solubilizer	10-20%
Edetate disodium	Chelating agent to prevent oxidation	0.01-0.1%

What are the key patent and regulatory considerations?

Patentability of excipient combinations remains significant, particularly for novel delivery systems or formulations. Regulatory agencies like the FDA emphasize standard excipient use with detailed formulation stability data.

• Patent opportunities: Innovative excipients or delivery devices can extend patent life.
• Regulatory pathways: Generally recognized as safe (GRAS) excipients streamline approval process.

What are commercial opportunities linked to excipient innovation?

Market growth and segments

• Migraine therapeutics: The global migraine drugs market reached USD 4.3 billion in 2020, with DHE-based products holding a niche share due to non-oral options.
• Innovative delivery systems: Nasal sprays with bioadhesive excipients or multi-use devices may command premium pricing.

R&D opportunities

• Formulation optimization: Enhancing stability and bioavailability via proprietary excipient blends.
• Delivery device innovation: Development of pre-filled nasal sprays or auto-injectors using novel excipients.

Regulatory and commercial leverage

• Validation of excipient stability enhances product shelf-life.
• Patent protection for novel excipient combinations creates market exclusivity.
• Improving patient compliance elevates market penetration.

What are competitive advantages of excipient strategy?

• Differentiation: Formulations with superior stability and improved absorption stand out.
• Manufacturing efficiency: Use of established excipients reduces regulatory hurdles.
• Intellectual property: Patents covering excipient compositions and delivery systems extend market exclusivity.

Summary of key considerations

Aspect	Implication
Stability enhancement	Less degradation, longer shelf life
Bioavailability improvement	Increased efficacy and dose reduction
Patient compliance	Non-invasive delivery options
Patent protection	Market exclusivity
Regulatory acceptance	Faster approval, reduced development risk

Key Takeaways

• Excipient choice for DHE affects stability, bioavailability, and patient acceptance.
• Innovative formulations and delivery systems create differentiation and patent opportunities.
• Market growth in migraine therapeutics supports investment in excipient R&D.
• Combining standard excipients with novel delivery devices enhances product value.
• Regulatory approval hinges on proven excipient safety and stability data.

FAQs

1. What excipients are commonly used in Dihydroergotamine Mesylate formulations?
Buffers (citric acid), preservatives (benzalkonium chloride), solubilizers (propylene glycol), and chelating agents (edetate disodium) are typical.

2. How does excipient selection influence DHE stability?
Excipients like antioxidants and chelating agents reduce oxidation, preserving drug potency during shelf life.

3. Can novel excipients extend DHE patent life?
Yes, unique combinations or delivery devices utilizing new excipients can be patented, prolonging exclusivity.

4. What are the regulatory considerations for excipients in DHE formulations?
Use of GRAS excipients with established safety profiles accelerates approval; deviations require extensive data.

5. What commercial opportunities exist for excipient innovation in DHE?
Improved formulations can command premium pricing, while novel delivery devices expand therapeutic options.

---

References

[1] European Medicines Agency. (2022). Guideline on excipient standards for medicinal products.
[2] U.S. Food and Drug Administration. (2019). Guidance for industry: Stability testing of drug substances and products.
[3] MarketWatch. (2021). Migraine therapeutics market analysis.
[4] PatentScope. (2022). Patent filings related to drug delivery excipients.